Navigation Links
First Bacterial Genome Transplantation Changing One Species to Another

Researchers at the J. Craig Venter Institute (JCVI) today announced the results of work on genome transplantation methods allowing them to transform one type of bacteria into another type dictated by the transplanted chromosome.

The work, published online in the journal Science, by JCVI's Carole Lartigue, Ph.D. and colleagues, outlines the methods and techniques used to change one bacterial species, Mycoplasma capricolum into another, Mycoplasma mycoides Large Colony (LC), by replacing one organism's genome with the other one's genome.

"The successful completion of this research is important because it is one of the key proof of principles in synthetic genomics that will allow us to realize the ultimate goal of creating a synthetic organism," said J. Craig Venter, Ph.D., president and chairman, JCVI.

"We are committed to this research as we believe that synthetic genomics holds great promise in helping to solve issues like climate change and in developing new sources of energy."

Methods and techniques>
The JCVI team devised several key steps to enable the genome transplantation. First, an antibiotic selectable marker gene was added to the M. mycoides LC chromosome to allow for selection of living cells containing the transplanted chromosome.

Then the team purified the DNA or chromosome from M. mycoides LC so that it was free from proteins (called naked DNA). This M. mycoides LC chromosome was then transplanted into the M. capricolum cells.

After several rounds of cell division, the recipient M. capricolum chromosome disappeared having been replaced by the donor M. mycoides LC chromosome, and the M. capricolum cells took on all the phenotypic characteristics of M. mycoides LC cells.

As a test of the success of the genome transplantation, the team used two methods -- 2D gel electrophoresis and protein sequencing, to prove that all the expressed proteins were now the ones co ded for by the M. mycoides LC chromosome.

Two sets of antibodies that bound specifically to cell surface proteins from each cell were reacted with transplant cells, to demonstrate that the membrane proteins switch to those dictated by the transplanted chromosome not the recipient cell chromosome. The new, transformed organisms show up as bright blue colonies in images of blots probed with M. mycoides LC specific antibody.

The group chose to work with these species of mycoplasmas for several reasons -- the small genomes of these organisms which make them easier to work with, their lack of cell walls, and the team's experience and expertise with mycoplasmas.

The mycoplasmas used in the transplantation experiment are also relatively fast growing, allowing the team to ascertain success of the transplantation sooner than with other species of mycoplasmas.

According to Dr. Lartigue, "While we are excited by the results of our research, we are continuing to perfect and refine our techniques and methods as we move to the next phases and prepare to develop a fully synthetic chromosome."

Genome transplantation is an essential enabling step in the field of synthetic genomics as it is a key mechanism by which chemically synthesized chromosomes can be activated into viable living cells.

The ability to transfer the naked DNA isolated from one species into a second microbial species paves the way for next experiments to transplant a fully synthetic bacterial chromosome into a living organism and if successful, "boot up" the new entity.

There are many important applications of synthetic genomics research including development of new energy sources and as means to produce pharmaceuticals, chemicals or textiles.




'"/>




Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First Artificial Heart patient has Major setback
5. First head-to-head trials of once weekly Fosamax and Actonel therapies
6. WHO Declares Vietnam First Country to Control SARS
7. Russia Reports First SARS Case
8. Hope for First New Melanoma Treatment in Decades
9. First global SARS meet opens
10. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
11. Hyderabad To Have Asia’s First Catheter Making Uni
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, ... as a standard feature on its secure clinical communication platform. The platform allows ... video depending on the type and urgency of a situation. , “We ...
(Date:5/23/2017)... ... 23, 2017 , ... New patients with symptoms of gum disease ... laser gum disease treatments from the doctors at Art of Dentistry, without first receiving ... of the importance of receiving qualified treatment in order to avoid systemic health effects ...
(Date:5/23/2017)... Horeb, WI (PRWEB) , ... May 23, 2017 , ... ... invited to call Dr. Angela Cotey’s practice to schedule an appointment, with or without ... services, and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative to ...
(Date:5/22/2017)... ... May 22, 2017 , ... Dr. Kiya Green, ... with periodontal plastic surgery treatments, including crown lengthening and gum reduction ... these esthetic and functional procedures to help patients improve their oral health, reduce ...
(Date:5/22/2017)... , ... May 22, 2017 , ... “Homeostasis: The Journey ... learning to live with Bipolar 1. Donald Rodriguez takes readers on a rollercoaster ride ... in the dead of winter and to a dark place where Donald considers suicide. ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... -- The Corporate Whistleblower Center says, "We are urging ... to call us anytime at 866-714-6466 if they possess ... a substantial scheme to overbill Medicare. We are ... of a medical equipment company if their employer ... practice groups with extra generous incentives to use, or ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
Breaking Medicine Technology: